The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

David M. Goldenberg; Rhona Stein; Robert M. Sharkey

doi:10.18632/oncotarget.25615

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

David M. Goldenberg _, Rhona Stein and Robert M. Sharkey

PDF | HTML | How to cite

Oncotarget. 2018; 9:28989-29006. https://doi.org/10.18632/oncotarget.25615

Metrics: PDF 5881 views | HTML 22704 views | ?

Abstract

David M. Goldenberg1,2, Rhona Stein1 and Robert M. Sharkey1,3

1Center for Molecular Medicine and Immunology, Belleville, NJ, USA

2IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA

3Immunomedics, Inc., Morris Plains, NJ, USA

Correspondence to:

David M. Goldenberg, email: [email protected]

Keywords: TROP-2; TACSTD2; sacituzumab govitecan; antibody-drug conjugates; immunotherapy

Received: April 30, 2018 Accepted: May 31, 2018 Published: June 22, 2018

ABSTRACT

TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes TROP-2’s properties, especially in cancer, and particularly its role as a target for antibody-drug conjugates (ADC) or immunotherapy. When the irinotecan metabolite, SN-38, is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan), it shows potent broad anticancer activity in human cancer xenografts and in patients with advanced triple-negative breast, non-small cell and small-cell lung, as well as urothelial cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25615

Publication Alerts

Reviews:

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

Abstract